Sanofi’s Genzyme Bid May Need to Reach $80 to Win Investors Sanofi-Aventis SA may have to pay at least $80 a share, or $21.3 billion, to acquire genetic-disease drugmaker Genzyme Corp. as activist directors drive up the price, investors in the U.S. biotechnology company say. Elizabeth Swann Poker face
Name (required)
Mail (will not be published) (required)
Website
